BRIEF published on 02/13/2025 at 07:05, 1 year 7 months ago SCHOTT Pharma Begins Fiscal Year 2025 with Promising Results Revenue Growth EBITDA Margin Q1 Results High-value Solutions DCS Segment
BRIEF published on 02/13/2025 at 07:05, 1 year 7 months ago SCHOTT Pharma débute l'année fiscale 2025 avec des résultats prometteurs Marge EBITDA Croissance Des Revenus Résultats Du Premier Trimestre Des Solutions À Haute Valeur Ajoutée Segment DCS
PRESS RELEASE published on 02/13/2025 at 07:00, 1 year 7 months ago SCHOTT Pharma records good start into fiscal year and confirms full year outlook SCHOTT Pharma reports good start in Q1 2025 with EUR 230m revenues, confirms full year outlook. EBITDA margin at 25.1% as reported. High-value solutions share at 55% Revenues EBITDA Margin SCHOTT Pharma Full Year Outlook Q1 2025
BRIEF published on 02/04/2025 at 18:27, 1 year 7 months ago SCHOTT Pharma Holds Successful Annual General Meeting Annual General Meeting Shareholder Approval SCHOTT Pharma Profit Growth MDAX Promotion
BRIEF published on 02/04/2025 at 18:27, 1 year 7 months ago SCHOTT Pharma organise avec succès son assemblée générale annuelle SCHOTT Pharma Assemblée Générale Annuelle Approbation Des Actionnaires Croissance Des Bénéfices Promotion MDAX
PRESS RELEASE published on 02/04/2025 at 18:22, 1 year 7 months ago SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items SCHOTT Pharma's successful Annual General Meeting for FY 2024 with all agenda items approved by shareholders, including new Supervisory Board member Dr. Wolfram Carius and KPMG as new auditor Annual General Meeting Shareholders SCHOTT Pharma KPMG Dr. Wolfram Carius
BRIEF published on 12/12/2024 at 07:05, 1 year 9 months ago SCHOTT Pharma Reports Strong Growth and Record Margins for FY 2024 Revenue Growth EBITDA Margin High-value Solutions Drug Delivery Systems Innovation And Expansion
BRIEF published on 12/12/2024 at 07:05, 1 year 9 months ago SCHOTT Pharma annonce une forte croissance et des marges record pour l'exercice 2024 Marge EBITDA Croissance Des Revenus Systèmes D'administration De Médicaments Des Solutions À Haute Valeur Ajoutée Innovation Et Expansion
PRESS RELEASE published on 12/12/2024 at 07:00, 1 year 9 months ago SCHOTT Pharma with strong growth and record margin after solid year-end finish SCHOTT Pharma AG & Co. KGaA reports strong growth and record margin for the fiscal year 2024, meeting 12% revenue growth target and achieving EBITDA margin of 27.8% Innovation Revenue EBITDA Margin SCHOTT Pharma Growth
BRIEF published on 12/04/2024 at 11:05, 1 year 9 months ago SCHOTT Pharma Introduces Efficient and Sustainable Cartridge Nest Design Sustainability GLP-1 Therapies Pharmaceutical Efficiency Cartridge Design Innovative Packaging
Published on 10/03/2026 at 02:35, 23 hours 18 minutes ago Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 13:50, 1 day 12 hours ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 12 hours ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 12 hours ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/03/2026 at 15:45, 10 hours 8 minutes ago Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 1 day 1 hour ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 5 hours ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 6 hours ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 19:00, 1 day 6 hours ago INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 10/02/2026 at 17:45, 1 day 8 hours ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 1 day 8 hours ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 1 day 8 hours ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 1 day 8 hours ago Aéroports de Paris SA - Calendrier financier 2027
